

Chronic Myelocytic Leukemia (CML) -Epidemiology Forecast to 2028

<https://marketpublishers.com/r/CC819353228EN.html>

Date: January 2019

Pages: 50

Price: US\$ 3,250.00 (Single User License)

ID: CC819353228EN

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Chronic Myelocytic Leukemia (CML) - Epidemiology Forecast, 2028' report provides a comprehensive analysis of the Chronic Myelocytic Leukemia (CML) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

MARKETS COVERED

United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2016-2028

Chronic Myelocytic Leukemia (CML) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Chronic Myelocytic Leukemia (CML) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Chronic Myelocytic Leukemia (CML) outlook. It also includes the explanation of

changing trends of epidemiology outlining the Chronic Myelocytic Leukemia (CML) scenario.

Chronic Myelocytic Leukemia (CML) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Chronic Myelocytic Leukemia (CML) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

REPORT SCOPE

The report covers detailed overview of Chronic Myelocytic Leukemia (CML) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

The Chronic Myelocytic Leukemia (CML) Report assesses the disease risk and burden and highlights the unmet needs

It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

10 Year Forecast

7MM Coverage

Total Cases in Chronic Myelocytic Leukemia (CML)

Key assessments

Patient Segmentation in Chronic Myelocytic Leukemia (CML)

Chronic Myelocytic Leukemia (CML) Risk & Burden

Factors driving growth in a specific Chronic Myelocytic Leukemia (CML) patient population

Contents

1. REPORT INTRODUCTION

2. CHRONIC MYELOCYTIC LEUKEMIA (CML) EPIDEMIOLOGY OVERVIEW AT A GLANCE

2.1. Patient Share Distribution of Chronic Myelocytic Leukemia (CML) in 2016

2.2. Patient Share Distribution of Chronic Myelocytic Leukemia (CML) in 2028

3. DISEASE BACKGROUND AND OVERVIEW: CHRONIC MYELOCYTIC LEUKEMIA (CML)

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Chronic Myelocytic Leukemia (CML) in 7MM

4.3. Total Prevalent/ Incident Patient Population of Chronic Myelocytic Leukemia (CML) in 7MM – By Countries

5. EPIDEMIOLOGY OF CHRONIC MYELOCYTIC LEUKEMIA (CML) BY COUNTRIES

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

5.1.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

5.1.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

5.1.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

5.2. EU5

5.3. Assumptions and Rationale

5.4. Germany

5.4.1. Assumptions and Rationale

5.4.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

5.4.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

5.4.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

5.4.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

5.5. France

5.5.1. Assumptions and Rationale

5.5.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

5.5.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

5.5.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

5.5.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

5.6. Italy

5.6.1. Assumptions and Rationale

5.6.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

5.6.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

5.6.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

5.6.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

5.7. Spain

5.7.1. Assumptions and Rationale

5.7.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

5.7.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

5.7.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

5.7.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

5.8. United Kingdom

5.8.1. Assumptions and Rationale

5.8.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

5.8.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

5.8.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

5.8.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

5.9. Japan

5.9.1. Assumptions and Rationale

5.9.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)

5.9.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)

5.9.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)

5.9.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)

6. UNMET NEEDS OF THE CHRONIC MYELOCYTIC LEUKEMIA (CML)

7. APPENDIX

8. REPORT METHODOLOGY

8.1. Sources

9. DELVEINSIGHT CAPABILITIES

10. DISCLAIMER

11. ABOUT DELVEINSIGHT

Indication Specific

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM

Table 2: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Table 5: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Table 6: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Table 7: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Table 8: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Table 9: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Table 10: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Table 11: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Table 12: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Table 13: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Table 14: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Table 15: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)

Table 16: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)

Table 17: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)

Table 18: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Italy

(2016-2028)

Table 19: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)

Table 20: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)

Table 21: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)

Table 22: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)

Table 23: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)

Table 24: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)

Table 25: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)

Table 26: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)

Table 27: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

Table 28: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

Table 29: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

Table 30: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

List Of Figures

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Figure 6: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)

Figure 7: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Figure 8: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Figure 9: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Figure 10: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)

Figure 11: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Figure 12: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Figure 13: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Figure 14: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)

Figure 15: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)

Figure 16: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)

Figure 17: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)

Figure 18: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Italy

(2016-2028)

Figure 19: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)

Figure 20: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)

Figure 21: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)

Figure 22: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)

Figure 23: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)

Figure 24: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)

Figure 25: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)

Figure 26: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)

Figure 27: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

Figure 28: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

Figure 29: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

Figure 30: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

I would like to order

Product name: Chronic Myelocytic Leukemia (CML) -Epidemiology Forecast to 2028

Product link: <https://marketpublishers.com/r/CC819353228EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC819353228EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970